TY - JOUR
T1 - A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis
AU - Magis, Delphine
AU - Ambrosini, Anna
AU - Sándor, Peter
AU - Jacquy, Jean
AU - Laloux, Patrice
AU - Schoenen, Jean
PY - 2007/1
Y1 - 2007/1
N2 - Background. - Impaired mitochondrial phosphorylation potential may play a role in migraine pathogenesis. Metabolic enhancers, such as riboflavin or coenzyme Q, are effective in migraine prophylaxis and quasi-devoid of adverse effects. Thioctic acid (-lipoïc acid) is another substance known to enhance energy metabolism in mitochondria and to be beneficial in diabetic neuropathy. Objective. - After an open pilot study suggesting its therapeutic antimigraine potentials, we embarked therefore in a randomized controlled trial of thioctic acid (Thioctacid) in migraine prophylaxis steered by the Belgian Headache Society. Methods. - Five Belgian centers recruited 54 migraineurs (43 migraine without aura, 11 with aura; mean age 38 ± 8 years; 7 males). After a 1-month single-blinded run-in period, 44 patients received either placebo (n = 18) or thioctic acid 600 mg p.o./day (n = 26) for 3 months. Results. - Statistical analysis was carried out on an intention-to-treat basis. Monthly attack frequency tended to be reduced between run-in and the 3rd month of treatment in the thioctic acid group compared to placebo (P =.06). The proportion of 50% responders was not significantly different between thioctic acid (30.8%) and placebo (27.8%). Within-group analyses showed a significant reduction of attack frequency (P =.005), headache days (P =.009), and headache severity (P =.03) in patients treated with thioctic acid for 3 months, while these outcome measures remained unchanged in the placebo group. No adverse effects were reported. For logistical reasons this trial was interrupted before the planned 80 patients were enrolled. Conclusion. - Albeit underpowered, this study tends to indicate that thioctic acid may be beneficial in migraine prophylaxis. Before any firm conclusion can be drawn, however, a large multicenter trial is necessary.
AB - Background. - Impaired mitochondrial phosphorylation potential may play a role in migraine pathogenesis. Metabolic enhancers, such as riboflavin or coenzyme Q, are effective in migraine prophylaxis and quasi-devoid of adverse effects. Thioctic acid (-lipoïc acid) is another substance known to enhance energy metabolism in mitochondria and to be beneficial in diabetic neuropathy. Objective. - After an open pilot study suggesting its therapeutic antimigraine potentials, we embarked therefore in a randomized controlled trial of thioctic acid (Thioctacid) in migraine prophylaxis steered by the Belgian Headache Society. Methods. - Five Belgian centers recruited 54 migraineurs (43 migraine without aura, 11 with aura; mean age 38 ± 8 years; 7 males). After a 1-month single-blinded run-in period, 44 patients received either placebo (n = 18) or thioctic acid 600 mg p.o./day (n = 26) for 3 months. Results. - Statistical analysis was carried out on an intention-to-treat basis. Monthly attack frequency tended to be reduced between run-in and the 3rd month of treatment in the thioctic acid group compared to placebo (P =.06). The proportion of 50% responders was not significantly different between thioctic acid (30.8%) and placebo (27.8%). Within-group analyses showed a significant reduction of attack frequency (P =.005), headache days (P =.009), and headache severity (P =.03) in patients treated with thioctic acid for 3 months, while these outcome measures remained unchanged in the placebo group. No adverse effects were reported. For logistical reasons this trial was interrupted before the planned 80 patients were enrolled. Conclusion. - Albeit underpowered, this study tends to indicate that thioctic acid may be beneficial in migraine prophylaxis. Before any firm conclusion can be drawn, however, a large multicenter trial is necessary.
KW - Energy metabolism
KW - Migraine prophylaxis
KW - Mitochondria
KW - Thioctic acid
UR - http://www.scopus.com/inward/record.url?scp=33846191544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846191544&partnerID=8YFLogxK
U2 - 10.1111/j.1526-4610.2006.00626.x
DO - 10.1111/j.1526-4610.2006.00626.x
M3 - Article
C2 - 17355494
AN - SCOPUS:33846191544
VL - 47
SP - 52
EP - 57
JO - Headache
JF - Headache
SN - 0017-8748
IS - 1
ER -